Tracon Pharmaceuticals Obtains $14,000,000 New Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=570bc98d-1f60-4b12-9b2a-a7f338a799c5&Preview=1 -
Date
4/1/2011 -
Company Name
Tracon Pharmaceuticals -
Mailing Address
8910 University Center Dr. San Diego, CA 92122 -
Company Description
TRACON Pharmaceuticals, Inc. is a fast growing biotechnology company developing next-generation targeted therapies for cancer and related diseases. We are addressing unmet needs in this arena with product candidates that focus on cellular targets specifically implicated in cancer growth and angiogenesis. -
Website
http://www.traconpharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$14,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
Proceeds from the financing will advance the development of the antibody TRC105, an inhibitor of angiogenesis that is being developed in multiple Phase 1b and Phase 2 indications, that are supported by the National Cancer Institute, including ongoing trials in prostate, bladder and liver cancer. -
M&A Terms
-
Venture Investor
Jafco Ventures -
Venture Investor
Nextech Invest -
Venture Investor
Arcus Ventures -
Venture Investor
Brookline Venture Partners -
Venture Investor
Undisclosed
